USTR Discusses TRIPS Waiver With Pfizer CEO, AstraZeneca Official
U.S. Trade Representative Katherine Tai published a readout of video calls she had with the leader of AstraZeneca's U.S. business and Pfizer's CEO on whether there should be a waiver of the World Trade Organization's agreement on Trade-Related Aspects of…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
Intellectual Property Rights (TRIPS). The readouts did not say what either the government or companies' positions are on a TRIPS waiver, and during a background call on aid to India to combat its surge of cases and deaths, an official also sidestepped a question on the waiver. The readouts said that Tai “emphasized her commitment to working with WTO members on a global pandemic response, including the role of developing countries in any effective solution that addresses critical gaps in global production and distribution of vaccines”; and that the Pfizer CEO also wants to improve global access to the vaccine, and he discussed “how trade policy could help address the challenges of increasing vaccine production and distribution around the world.”